Novavax is a biotechnology company based in Gaithersburg, Maryland, focused on developing recombinant vaccines, including its COVID-19 vaccines Nuvaxovid and other candidates. The company employs 1,543 people and utilizes advanced nanoparticle technology and its Matrix-M adjuvant to enhance immune responses.
Novavax (NVAX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Novavax's actual EPS was -$0.83, missing the estimate of -$0.52 per share, resulting in a -58.31% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
